141 related articles for article (PubMed ID: 35218767)
21. Plant sterol ester of α-linolenic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice: association with regulating mitochondrial dysfunction and oxidative stress via activating AMPK signaling.
Han H; Li X; Guo Y; Zheng M; Xue T; Wang L
Food Funct; 2021 Mar; 12(5):2171-2188. PubMed ID: 33566044
[TBL] [Abstract][Full Text] [Related]
22. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
23. The promotion of fatty acid β-oxidation by hesperidin
Nie T; Wang X; Li A; Shan A; Ma J
Food Funct; 2024 Jan; 15(1):372-386. PubMed ID: 38099440
[TBL] [Abstract][Full Text] [Related]
24. Baicalein reduces hepatic fat accumulation by activating AMPK in oleic acid-induced HepG2 cells and high-fat diet-induced non-insulin-resistant mice.
Sun W; Liu P; Wang T; Wang X; Zheng W; Li J
Food Funct; 2020 Jan; 11(1):711-721. PubMed ID: 31909773
[TBL] [Abstract][Full Text] [Related]
25. β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway.
Xu N; Luo H; Li M; Wu J; Wu X; Chen L; Gan Y; Guan F; Li M; Su Z; Chen J; Liu Y
Biomed Pharmacother; 2021 Feb; 134():111104. PubMed ID: 33341045
[TBL] [Abstract][Full Text] [Related]
26. Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models.
Zhang Y; Meng T; Zuo L; Bei Y; Zhang Q; Su Z; Huang Y; Pang J; Xiang Q; Yang H
Mar Drugs; 2017 Jun; 15(6):. PubMed ID: 28587208
[TBL] [Abstract][Full Text] [Related]
27. Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease.
Zhang H; Yang L; Wang Y; Huang W; Li Y; Chen S; Song G; Ren L
Life Sci; 2020 Sep; 257():118090. PubMed ID: 32679144
[TBL] [Abstract][Full Text] [Related]
28. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
[No Abstract] [Full Text] [Related]
29. Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway.
Li N; Yin L; Shang J; Liang M; Liu Z; Yang H; Qiang G; Du G; Yang X
Biomed Pharmacother; 2023 Sep; 165():115113. PubMed ID: 37418974
[TBL] [Abstract][Full Text] [Related]
30.
Bae S; Lee YH; Lee J; Park J; Jun W
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558538
[No Abstract] [Full Text] [Related]
31. Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome.
Shen Q; Chen Y; Shi J; Pei C; Chen S; Huang S; Li W; Shi X; Liang J; Hou S
Eur J Pharmacol; 2023 Mar; 942():175504. PubMed ID: 36641101
[TBL] [Abstract][Full Text] [Related]
32. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.
Seo MS; Kim JH; Kim HJ; Chang KC; Park SW
Toxicol Appl Pharmacol; 2015 Apr; 284(2):113-24. PubMed ID: 25737164
[TBL] [Abstract][Full Text] [Related]
33.
Park M; Yoo JH; Lee YS; Lee HJ
Nutrients; 2019 Feb; 11(3):. PubMed ID: 30813654
[TBL] [Abstract][Full Text] [Related]
34.
Park SS; Lee YJ; Song S; Kim B; Kang H; Oh S; Kim E
J Endocrinol; 2018 May; 237(2):87-100. PubMed ID: 29507043
[TBL] [Abstract][Full Text] [Related]
35. A novel AMPK activator, WS070117, improves lipid metabolism discords in hamsters and HepG2 cells.
Lian Z; Li Y; Gao J; Qu K; Li J; Hao L; Wu S; Zhu H
Lipids Health Dis; 2011 Apr; 10():67. PubMed ID: 21529359
[TBL] [Abstract][Full Text] [Related]
36. Vine tea total flavonoids activate the AMPK/mTOR pathway to amelioration hepatic steatosis in mice fed a high-fat diet.
Wang C; Yang F; Zeng W; Chen X; Qiu Z; Wang Q; Meng Y; Zheng G; Hu J
J Food Sci; 2024 May; 89(5):3019-3036. PubMed ID: 38517018
[TBL] [Abstract][Full Text] [Related]
37. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling.
Kim MH; Seong JB; Huh JW; Bae YC; Lee HS; Lee DS
Redox Biol; 2020 Jan; 28():101315. PubMed ID: 31505325
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-205 ameliorates lipid accumulation in non-alcoholic fatty liver disease through targeting NEU1.
Hu Y; Ye H; Shi LX
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):10072-10082. PubMed ID: 31799678
[TBL] [Abstract][Full Text] [Related]
39. Mangiferin Ameliorates HFD-Induced NAFLD through Regulation of the AMPK and NLRP3 Inflammasome Signal Pathways.
Yong Z; Ruiqi W; Hongji Y; Ning M; Chenzuo J; Yu Z; Zhixuan X; Qiang L; Qibing L; Weiying L; Xiaopo Z
J Immunol Res; 2021; 2021():4084566. PubMed ID: 34734090
[TBL] [Abstract][Full Text] [Related]
40. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
Liu Q; Pan R; Ding L; Zhang F; Hu L; Ding B; Zhu L; Xia Y; Dou X
Int Immunopharmacol; 2017 Aug; 49():132-141. PubMed ID: 28577437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
